- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
A rheumatoid factor paradox: inhibition of rituximab effector function ; volume:15 ; number:1 ; day:25 ; month:1 ; year:2013 ; pages:1-11 ; date:2.2013
Arthritis Research & Therapy ; 15, Heft 1 (25.1.2013), 1-11, 2.2013
- Creator
-
Jones, Jonathan D.
- Contributor
-
Shyu, Irene
Newkirk, Marianna M.
Rigby, William FC
SpringerLink (Online service)
- DOI
-
10.1186/ar4152
- URN
-
urn:nbn:de:1111-2016050324969
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:52 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Jones, Jonathan D.
- Shyu, Irene
- Newkirk, Marianna M.
- Rigby, William FC
- SpringerLink (Online service)
Other Objects (12)
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
A rare association of rheumatoid arthritis and primary biliary cirrhosis treated with rituximab: a case report
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
A rare association of rheumatoid arthritis and primary biliary cirrhosis treated with rituximab: a case report
Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
Seronegative and seropositive rheumatoid arthritis treated with rituximab
Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis
Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Posterior reversible encephalopathy syndrome: A rare complication of rituximab therapy in rheumatoid arthritis
Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis
Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab
Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment
Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial
Comparing immunogenicity and safety following transition from reference rituximab to biosimilar rituximab (DRL_RI) in patients with rheumatoid arthritis: a randomized, double-blind, phase 3 study
The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients
A rare association of rheumatoid arthritis and primary biliary cirrhosis treated with rituximab: a case report